1261395-96-3
1261395-96-3
Chemical Structure
4-Hydroxyphenyl Carvedilol-d5
Synonym(s): 4-Hydroxycarvedilol-d5
- CAS No.: 1261395-96-3
- Formula:C24H21D5N2O5
- Molecular Weight:427.50
IUPAC Name: 4-(2-((3-((9H-carbazol-4-yl)oxy)-2-hydroxypropyl-1,1,2,3,3-d5)amino)ethoxy)-3-methoxyphenol
InChIKey: ZCJHEORDHXCJNB-SUPLBRQZSA-N
SMILES: OC(C([2H])([2H])NCCOC1=CC=C(O)C=C1OC)([2H])C([2H])([2H])OC2=CC=CC3=C2C4=C(C=CC=C4)N3
Biological Activity: 4-Hydroxyphenyl Carvedilol-d5 is the deuterium labeled 4-Hydroxyphenyl Carvedilol.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
4-Hydroxyphenyl Carvedilol-d5 | 4-Hydroxyphenyl Carvedilol-d5 is the deuterium labeled 4-Hydroxyphenyl Carvedilol. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carvedilol metabolite 4-Hydroxyphenyl Carvedilol-13C6 | Carvedilol metabolite 4-Hydroxyphenyl Carvedilol-13C6 (4-Hydroxycarvedilol Carvedilol-13C6) is 13C labeled Carvedilol metabolite 4-Hydroxyphenyl Carvedilol. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carvedilol metabolite 4-Hydroxyphenyl Carvedilol-d4 | Carvedilol metabolite 4-Hydroxyphenyl Carvedilol-d4 is deuterated labeled Carvedilol metabolite 4-Hydroxyphenyl Carvedilol (HY-12767). 4-Hydroxyphenyl Carvedilol is a metabolite of Carvedilol. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4’-Hydroxyphenyl Carvedilol-d3 | 4’-Hydroxyphenyl Carvedilol-d3 is the deuterium labeled 4’-Hydroxyphenyl Carvedilol. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carvedilol metabolite 4-Hydroxyphenyl Carvedilol | 98.42% | 4-Hydroxyphenyl Carvedilol, a metabolite of Carvedilol, is an active metabolite of Carvedilol (HY-B0006) and is produced via CYP2D6-mediated oxidation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VK-II-86 | 93.33% | VK-II-86 is a Carvedilol (HY-B0006) analogue lacking antagonist activity at β-adrenoceptors, in hypokalaemia. VK-II-86 prevents hypokalaemia-induced ventricular arrhythmia through multi-channel effects. VK-II-86 prevents all hypokalaemia-induced changes in ion channel activity and oxidative stress. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB209995 | SB209995 is an active compound. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-Hydroxy carvedilol | 3-Hydroxy carvedilol is an active compound. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S)-Carvedilol (Standard) | ≥98% | (S)-Carvedilol (Standard) is the analytical standard of (S)-Carvedilol. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-Carvedilol | 98.78% | (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca2+ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carvedilol (Standard) | 99.92% | Carvedilol (Standard) is the analytical standard of Carvedilol. This product is intended for research and analytical applications. Carvedilol (BM 14190) is a non-selective β/α-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carvedilol-d3 | 98.57% | Carvedilol-d3 is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carvedilol impurity 8 | Carvedilol impurity 8 is an impurity of Carvedilol. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
O-Desmethylcarvedilol | 97.4% | O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of the non-selective β-adrenergic receptor (β-AR) antagonist Carvedilol (HY-B0006). O-Desmethylcarvedilol inhibits store-overload-induced calcium release in HEK293 cells expressing the ryanodine receptor 2 (RyR2) R4496C (RyR2R4496C) mutation (IC50 = 7.62 µM). O-Desmethylcarvedilol reduces increases in heart rate and prevents decreases in diastolic blood pressure induced by Isoproterenol (HY-B0468) in conscious rabbits (ED50s = 32 and 5 µg/kg, respectively). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
